BioInvent International is a clinical-stage biotech company that discovers and
develops novel and first-in-class immuno-modulatory antibodies for cancer
therapy. We have several drug candidates in our ongoing clinical programs in
Phase 1/2 trials for the treatment of hematological cancer as well as solid
tumors.
At BioInvent, we are focused on enrolling and conducting the clinical trials
necessary to gain regulatory approvals to make our medicines available to
patients as quickly as possible. As such, we believe participation in our clinical
trial is the most appropriate way to access our new treatments at this early stage
of development.
BioInvent understands the interest of patients and healthcare providers in
accessing new therapies outside of clinical trials and prior to being available on
the market for potentially life-threatening diseases. However, we do not offer
any of our developmental medicines through expanded access programs, except
for patients who could benefit for continued treatment upon completion of one
of our clinical trials. We recognize the need for Expanded Access programs and
will re-evaluate the status of our policy based on emerging data from ongoing
and future clinical trials.
BioInvent International is a clinical-stage biotech company that discovers and
develops novel and first-in-class immuno-modulatory antibodies for cancer
therapy. We have several drug candidates in our ongoing clinical programs in
Phase 1/2 trials for the treatment of hematological cancer as well as solid
tumors.
At BioInvent, we are focused on enrolling and conducting the clinical trials
necessary to gain regulatory approvals to make our medicines available to
patients as quickly as possible. As such, we believe participation in our clinical
trial is the most appropriate way to access our new treatments at this early stage
of development.
BioInvent understands the interest of patients and healthcare providers in
accessing new therapies outside of clinical trials and prior to being available on
the market for potentially life-threatening diseases. However, we do not offer
any of our developmental medicines through expanded access programs, except
for patients who could benefit for continued treatment upon completion of one
of our clinical trials. We recognize the need for Expanded Access programs and
will re-evaluate the status of our policy based on emerging data from ongoing
and future clinical trials.

We encourage those who are interested in learning more about our clinical
development programs, including eligibility criteria and locations to visit
clinicaltrials.gov